Cocrystal Pharma, Inc. financial data

Symbol
COCP on Nasdaq
Location
Bothell, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 466% % -45.4%
Debt-to-equity 44.4% % 112%
Return On Equity -130% % -37.1%
Return On Assets -89.8% % -14.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,784,065 shares 35.5%
Common Stock, Shares, Outstanding 13,041,000 shares 28.2%
Entity Public Float $18,000,000 USD -2.7%
Common Stock, Value, Issued $13,000 USD 30%
Weighted Average Number of Shares Outstanding, Basic 10,991,000 shares 8.03%
Weighted Average Number of Shares Outstanding, Diluted 10,991,000 shares 8.03%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,473,000 USD -62.9%
General and Administrative Expense $4,295,000 USD -22.6%
Operating Income (Loss) $-9,768,000 USD 49.4%
Nonoperating Income (Expense) $97,000 USD -84.2%
Net Income (Loss) Attributable to Parent $-9,671,000 USD 48.3%
Earnings Per Share, Basic 0 USD/shares 48.9%
Earnings Per Share, Diluted 0 USD/shares 48.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,860,000 USD -62.6%
Assets, Current $8,782,000 USD -38.4%
Property, Plant and Equipment, Net $106,000 USD -41.4%
Operating Lease, Right-of-Use Asset $1,468,000 USD -16.9%
Assets $10,446,000 USD -35.6%
Accounts Payable, Current $745,000 USD -13.3%
Employee-related Liabilities, Current $127,000 USD -31.4%
Liabilities, Current $1,520,000 USD -22%
Operating Lease, Liability, Noncurrent $1,257,000 USD -20.5%
Liabilities $2,777,000 USD -21.3%
Retained Earnings (Accumulated Deficit) $-339,823,000 USD -2.93%
Stockholders' Equity Attributable to Parent $7,669,000 USD -39.6%
Liabilities and Equity $10,446,000 USD -35.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-2,939,000 USD 34.7%
Net Cash Provided by (Used in) Investing Activities $-8,000 USD 82.2%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 13,041,000 shares 28.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $-2,939,000 USD 34.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,095,000 USD
Deferred Tax Assets, Valuation Allowance $35,218,000 USD 11.9%
Deferred Tax Assets, Gross $35,605,000 USD 11.5%
Operating Lease, Liability $1,583,000 USD -15.6%
Payments to Acquire Property, Plant, and Equipment $8,000 USD -82.2%
Lessee, Operating Lease, Liability, to be Paid $1,825,000 USD -18.1%
Property, Plant and Equipment, Gross $2,094,000 USD 0.58%
Operating Lease, Liability, Current $326,000 USD 11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $415,000 USD -0.96%
Lessee, Operating Lease, Liability, to be Paid, Year One $419,000 USD 2.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $242,000 USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three $376,000 USD -9.4%
Deferred Tax Assets, Operating Loss Carryforwards $23,672,000 USD 7.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $249,000 USD -33.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $35,218,000 USD 11.9%
Share-based Payment Arrangement, Expense $282,000 USD -19.2%
Interest Expense $-220,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%